Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch

Regentis, Cuprina, and Intellia were among today's top gainers, driven by company-specific catalysts. Regentis fell after withdrawing a planned U.S. listing application (Form F-1) with the SEC, while Cuprina rose on FDA clearance for its maggot debridement therapy and Intellia advanced after reporting additional positive results. The article is broadly constructive for biotech sentiment, with the strongest positive read-through tied to regulatory progress.

Analysis

Regentis, Cuprina, and Intellia were among today's top gainers, driven by company-specific catalysts. Regentis fell after withdrawing a planned U.S. listing application (Form F-1) with the SEC, while Cuprina rose on FDA clearance for its maggot debridement therapy and Intellia advanced after reporting additional positive results. The article is broadly constructive for biotech sentiment, with the strongest positive read-through tied to regulatory progress.